Femasys Inc
Stock Watch
Stock Watch will tell you what changes at Femasys Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.306 $ to 5.40 $ · Last price: 1.30 $ (As of: November 2, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 11/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Instruments & Supplies
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Femasys Inc FEMY | 0.0 | – | 0.2 | 61.0 | – | 40.8 | -89.6 |
| Intuitive Surgical Inc ISRG | 154.7 | 55.6 | 33.8 | 66.6 | 30.9 | 20.5 | -18.2 |
| Becton Dickinson and Company BDX | 54.7 | 36.1 | 14.3 | 46.9 | 14.7 | 8.2 | 43.8 |
| Medline Inc. MDLN | 45.2 | 28.1 | 14.0 | 25.1 | 5.4 | 11.5 | – |
| ResMed Inc RMD | 33.3 | 22.6 | 16.2 | 61.6 | 35.3 | 9.8 | -7.9 |
| West Pharmaceutical Services Inc WST | 28.2 | 55.2 | 31.2 | 36.8 | 21.7 | 6.3 | 48.6 |
| Solventum Corp. SOLV | 14.6 | 10.4 | 7.9 | 54.8 | 5.6 | 0.9 | 22.8 |
| Baxter International Inc BAX | 12.2 | – | 27.0 | 34.1 | 6.0 | 5.7 | 31.4 |
| The Cooper Companies, Inc COO | 11.8 | 53.6 | 15.0 | 65.9 | -2.9 | 5.1 | -12.3 |
| Median of companies shown | 28.2 | 36.1 | 15.0 | 54.8 | 10.4 | 8.2 | 7.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 1 | -12 | -11 | -19.17 | -11 | -45 | 13 |
| 2020 | 1 | -7 | -7 | -11.76 | -5 | 4 | 8 |
| 2021 | 1 | -8 | -8 | -12.77 | -8 | 26 | 29 |
| 2022 | 1 | -12 | -11 | -19.31 | -11 | 15 | 17 |
| 2023 | 1 | -15 | -14 | -18.52 | -11 | 18 | 28 |
| 2024 | 2 | -18 | -19 | -16.91 | -19 | 2 | 12 |
| 2025 | 2 | -18 | -19 | -9.42 | -19 | 6 | 21 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.70 | – | 1 | 173.20 | -880.40 | -5 | -5 |
| 2025: Q1 | -1.95 | – | 0 | 25.80 | -1,729.30 | -5 | -5 |
| 2025: Q2 | -1.52 | – | 0 | 85.10 | -1,121.30 | -4 | -4 |
| 2025: Q3 | -1.39 | – | 1 | 31.40 | -575.40 | -5 | -6 |
| 2025: Q4 | -1.31 | – | 1 | 39.70 | -485.90 | -4 | -4 |
| 2026: Q1 | 0.11 | – | 0 | 24.60 | 77.40 | -4 | -4 |
| 2026: Q2 | -1.33 | 12.50 | 0 | -25.00 | -1,500.00 | -4 | -4 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.60 | -3.03 – -2.17 | 2 | 36.2% | 2 |
| 12/31/2027 | -2.13 | -2.59 – -1.66 | 9 | 26.8% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 23.9%
- More than 10% revenue growth is expected for the coming year 165.6%
- Share count grows by less than 3% a year 49.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -797.1%
- Gross margin at 40% or higher and without meaningful erosion 62.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 5 m net cash
- Operating cash flow covers the profits of the last three years 2 m
- Return on capital at 15% or higher, or up versus two years ago -102.9%
- Insiders hold at least 10% or are net buyers 9.3%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 16.2%
- Exp. sales growth 3Y > 5% 97.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 97.1%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -324.9%
- ROCE > 15% -102.9%
- Expected return > 10% -849.9%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Mifek Jeffrey Gerald | Chief Clinical-Medical Affairs | Buy | 3,125 | 3.20 | 10,000 |
| Aug 7, 2026 | Sipos Jeremy Alexander | Chief Technology Officer | Buy | 3,125 | 3.20 | 10,000 |
| Aug 7, 2026 | Canning John Charles | Chief Operating Officer | Buy | 4,375 | 3.20 | 14,000 |
| Aug 7, 2026 | Elefant Dov | Chief Financial Officer | Buy | 15,625 | 3.20 | 50,000 |
| Aug 7, 2026 | Lee-Sepsick Kathy | Chief Executive Officer | Buy | 15,625 | 3.20 | 50,000 |
The company
About the Company
Femasys Inc., ein biomedizinisches Unternehmen, entwickelt und vermarktet therapeutische und diagnostische Produkte für die reproduktive Gesundheit von Frauen in den USA und international.
- Employees
- 51
- Headquarters
- Suwanee, GA
- Address
- 3950 Johns Creek Court, 30024 Suwanee, United States
- Phone
- 770 500 3910
- Website
- femasys.com
- IPO Date
- 06/18/2021
- ISIN
- US31447E2046
- Stock Split
- 1:20 on 06/08/2026
Management
| Name | Title | Birth Year |
|---|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, CEO & Director | 1968 |
| Dov Elefant | Chief Financial Officer | 1967 |
| John Canning | Chief Operating Officer | 1974 |
| Jeremy Alexander Sipos M.S. | Chief Technology Officer | 1974 |
| James H. Liu M.D. | Chief Medical Officer | – |
| Jeffrey Gerald Mifek | Chief Clinical & Regulatory Affairs Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 11/02/2026 FEMASYS INC (FEMY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/14/2026 FEMASYS INC (FEMY): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 08/11/2026 FEMASYS INC (FEMY): Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Statements and Exhibits SEC ↗
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.